Bob Dess, MD
MROQC Program Co-Director
Dr. Dess is a Co-Director for MROQC and is also the Co-Clinical lead of the MROQC Prostate Cancer Working Group. Dr. Dess is an Assistant Professor in the Department of Radiation Oncology at the University of Michigan. He attended medical school at the University of Chicago and completed his residency in radiation oncology at the University of Michigan where he joined the faculty upon completion of his training.
He practices in several locations. At the University of Michigan Ann Arbor main campus, he is the Co-Chief of the Genitourinary Radiotherapy Service and also leads the high dose rate (HDR) prostate brachytherapy program. At the Brighton Center for Specialty Care, he serves as the primary genitourinary radiation oncologist.
Dr. Dess is a clinical and translational researcher focused on genitourinary malignancy. He has worked with a global network of collaborators to create novel prognostic models to characterize prostate cancer disease aggressiveness, to identify novel prognostic and predictive biomarkers, to analyze racial outcomes differences and settings in which disparities are minimized, and to advance more convenient forms of treatment including stereotactic body radiation therapy (SBRT) and high-dose rate brachytherapy (HDR). He is interested in maximizing efficacy, minimizing burden, and understanding the long-term toxicity risks of treatment. His work has been published high profile in peer-reviewed journals including the New England Journal of Medicine, Journal of Clinical Oncology, and JAMA Oncology.